GCA
SLS icon

Genesee Capital Advisors’s SELLAS Life Sciences SLS Stock Holding History

Genesee Capital Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$443K Hold
30,000
– – 0.14% 109
2026
Q1 		$127K Hold
30,000
– – 0.05% 133
2025
Q4 		$113K Hold
30,000
– – 0.05% 126
2025
Q3 		$48.3K Buy
+30,000
New +$53.4K 0.02% 123

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Genesee Capital Advisors's SLS Position: Q2 2026 in Review

Genesee Capital Advisors held its SELLAS Life Sciences (SLS) position steady in Q2 2026 at 30,000 shares worth $443K. The position accounts for 0.14% of the portfolio, ranked #109.

Genesee Capital Advisors first reported a position in SLS in Q3 2025 and has held it in 4 quarters since. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Genesee Capital Advisors held 30,000 shares of SELLAS Life Sciences worth $443K as of Q2 2026.
  • Genesee Capital Advisors left its SELLAS Life Sciences share count unchanged in Q2 2026.
  • SELLAS Life Sciences made up 0.14% of Genesee Capital Advisors's portfolio in Q2 2026, its #109 holding.
  • Genesee Capital Advisors first reported a position in SELLAS Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Genesee Capital Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.